How did Rubicon Research's profitability change in FY26?

Net profit surged 83.6% to ₹246.74 crore, up from ₹134.36 crore in FY25. This growth significantly outpaced the 36.6% increase in revenue, indicating a widening spread between sales growth and profit growth.

What dividend did the company declare?

The Board of Directors recommended a final dividend of ₹1.50 per equity share for the fiscal year ended March 31, 2026.

Were the results audited, and if so, what was the outcome?

The results were audited by Deloitte Haskins & Sells LLP. The audit opinion was unmodified, meaning the financial statements were presented fairly without any qualifications.

What was the quarterly revenue figure?

Revenue for the March 2026 quarter rose to ₹513.92 crore. This is part of the full-year consolidated results for the period ending March 31, 2026.

Earnings · Pharmaceuticals · Mid cap

Rubicon Research's profit runs twice as fast as sales in FY26

Annual net profit jumped 83.6% to ₹246.74 cr on 36.6% revenue growth. The board declared a ₹1.50 per share dividend.

— 1 earlier story on Rubicon Research Ltd. →

RUBICON By Tipsheet Editorial 29 May 2026 · 7:22 PM IST Verify on BSE · NSE

Mkt cap₹16,602 cr

P/E123.56×

ROE24.84%

Debt / eq.0.73

Div yld0.00%

83.6% Jump in Rubicon Research's annual net profit.

What's new

Consolidated revenue for FY26 rose 36.6% to ₹1,753.96 cr.
Net profit surged 83.6% to ₹246.74 cr from ₹134.36 cr in FY25.
Board recommended a final dividend of ₹1.50 per equity share.

Why this matters

The results show profit growing more than twice as fast as revenue. That points to a widening gap between what Rubicon earns and what it spends to operate. The specialty pharma company is turning top-line growth into bottom-line gains at an accelerating pace.

What we're watching

Whether the strong profit growth rate holds in the quarters ahead.
How the specialty pharma pipeline develops.
The dividend payout ratio in future years.

The full read

Rubicon Research just posted a year where profits ran twice as fast as sales. Annual revenue climbed 36.6% to ₹1,753.96 crore, but net profit jumped 83.6% to ₹246.74 crore, up from ₹134.36 crore the year before. The specialty pharma company is turning top-line growth into bottom-line gains at a faster clip. The quarterly breakdown shows revenue of ₹513.92 crore for the March period. The board has also declared a final dividend of ₹1.50 per share. Deloitte signed off with an unmodified opinion, giving a clean set of audited numbers to work with. The headline: profit growth is more than double revenue growth. That's the story.

Questions answered

How did Rubicon Research's profitability change in FY26?: Net profit surged 83.6% to ₹246.74 crore, up from ₹134.36 crore in FY25. This growth significantly outpaced the 36.6% increase in revenue, indicating a widening spread between sales growth and profit growth.
What dividend did the company declare?: The Board of Directors recommended a final dividend of ₹1.50 per equity share for the fiscal year ended March 31, 2026.
Were the results audited, and if so, what was the outcome?: The results were audited by Deloitte Haskins & Sells LLP. The audit opinion was unmodified, meaning the financial statements were presented fairly without any qualifications.
What was the quarterly revenue figure?: Revenue for the March 2026 quarter rose to ₹513.92 crore. This is part of the full-year consolidated results for the period ending March 31, 2026.

Mentioned: Rubicon Research Ltd · Deloitte Haskins & Sells LLP · ₹1.50 per share dividend

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on RUBICON →

29 May 2026 · 7:22 PM IST Rubicon Research's profit runs twice as fast as sales in FY26
1d ago Rubicon's profit doubles, but growth is outpacing its own factories